title: Big costs for little gain in ovarian cancer.
authors.forename: Martee L
authors.initials: ML
authors.lastname: Hensley
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000191:economics; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D000068258:Bevacizumab; D016190:Carboplatin / Q000008:administration & dosage / Q000191:economics; D003362:Cost-Benefit Analysis; D018572:Disease-Free Survival; D016527:Drug Costs; D005260:Female; D006801:Humans; D007416:Intestinal Perforation / Q000191:economics / Q000209:etiology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000191:economics* / Q000401:mortality; D017239:Paclitaxel / Q000008:administration & dosage / Q000191:economics; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016190:Carboplatin; D017239:Paclitaxel